ProstACT Global Phase 3 (Part 1) Achieves Primary Objectives
Filed with ASX · · 4 pages · English
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings CallTelix Pharmaceuticals Limited on 6ix
In the deck
Story so far
Earlier from Telix Pharmaceuticals
- Investor Education Webinar
- Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging
- Telix to Participate in Oppenheimer and TD Cowen Conferences
- FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
- 2025 Full Year Results Presentation
Later from Telix Pharmaceuticals
- Telix Resubmits NDA to FDA for Pixclara Brain Cancer Imaging
- Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate
- Telix selects IBA Cyclone® KIUBE to support manufacturing expansion in the U.S.
- Telix Appoints David Gill as Non-Executive Director
- Q1 2026 Strong Revenue Growth and Tx Pipeline Advancement
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals